In:
Respiration, S. Karger AG, Vol. 75, No. 4 ( 2008), p. 443-449
Abstract:
〈 i 〉 Background: 〈 /i 〉 Despite being commercially available for a few years now, the literature regarding the outcome of UltraflexTM stent insertion in complex malignant airway stenoses is sparse. 〈 i 〉 Objectives: 〈 /i 〉 To assess long-term complications and survival in patients with complex malignant airway stenoses treated with insertion of nitinol stents. 〈 i 〉 Methods: 〈 /i 〉 60 consecutive patients with UltraflexTM stent insertion for malignant airway stenoses were included. Follow-up was obtained in all patients. 〈 i 〉 Results: 〈 /i 〉 62 UltraflexTM stents (covered = 51, uncovered = 11) were implanted in 60 patients. Diagnoses were bronchial carcinoma (n = 50), esophageal carcinoma (n = 3) and metastases (n = 7). Stents were inserted in the trachea (n = 5), main bronchi/intermediate bronchus (n = 22), from main bronchi/intermediate bronchus to lobar bronchi (n = 28) or in the lobar bronchi themselves (n = 7). Successful reopening of the stenoses and relief were achieved in all patients. There was no procedure-related mortality. Complications included mucous plugging in 8%, stenosing granulation tissue in 5%, tumor ingrowth in 5% and stent migration in 5% of patients. Using Kaplan-Meier estimates, the overall mean survival was 160 days (standard error: 30). Median survival was 91 days. The overall 3- and 6-month survival were 52 and 20%, respectively. Death (n = 59, 98%) was attributed mainly to disease progression with cachexia and metastases, pneumonia (n = 5, 10%), and hemoptysis (n = 1, 2%). 〈 i 〉 Conclusion: 〈 /i 〉 UltraflexTM stents have a low complication rate and can be effectively used in complex malignant airway stenoseswith marked asymmetry or irregularity, angulation or changing diameters.
Type of Medium:
Online Resource
ISSN:
0025-7931
,
1423-0356
Language:
English
Publisher:
S. Karger AG
Publication Date:
2008
detail.hit.zdb_id:
1464419-8
